Lupus & antiphospholipid syndrome
Evaluating the concordance between BICLA and SRI4 in patients with systemic lupus erythematosus from the placebo arms of the EXPLORER and ATHOS trials
Authors' conclusion
BICLA and SRI4 may be discordant in SLE trials. Arthritis and rash were the primary drivers of the discordance, and serology influenced BICLA and SRI4 response
Study context
- Population
- Participants with SLE receiving placebo and standard of care (SOC) in two RCTs
- Participants
- 87 vs 80
- Comparison
- BICLA vs SRI4 response in placebo participants
- EXPLORERn = 87
- ATHOSn = 80
Primary result
As reported in the abstract
week 52 (EXPLORER), week 48 (ATHOS)
Values · week 52 (EXPLORER), week 48 (ATHOS) EXPLORER Cohen's κ 0.46 · ATHOS Cohen's κ 0.54
BICLA response rate
SRI4 response rate
BICLA+/SRI4- discordance
BICLA-/SRI4+ discordance
Further findings
BICLA response by baseline manifestation (ATHOS subgroups) · week 48
Discordance by baseline complement
- BICLA-/SRI4+ and BICLA+/SRI4- discordance lower with low vs normal complement at baseline
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Evaluating the concordance between BICLA and SRI4 in patients with systemic lupus erythematosus from the placebo arms of the EXPLORER and ATHOS trials. Lupus Sci Med. Published 19 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →